{
    "info": {
        "nct_id": "NCT02872714",
        "official_title": "A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)",
        "inclusion_criteria": "* 20 years and older in Japan\n* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Life expectancy ≥ 12 weeks.\n* Radiographically measurable per RECIST v1.1.\n* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior receipt of a selective FGFR inhibitor.\n* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.\n* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically measurable per RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Radiographically measurable per RECIST v1.1.",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "RECIST v1.1"
                        },
                        {
                            "requirement_type": "assessment modality",
                            "expected_value": "radiographic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 12 weeks.",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 20 years and older in Japan",
            "criterions": [
                {
                    "exact_snippets": "20 years and older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in Japan",
                    "criterion": "location",
                    "requirements": [
                        {
                            "requirement_type": "country of residence",
                            "expected_value": "Japan"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder.",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented metastatic or surgically unresectable urothelial carcinoma",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "metastatic",
                                "surgically unresectable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "may include primary site from urethra, ureters, upper tract, renal pelvis, and bladder",
                    "criterion": "primary tumor site",
                    "requirements": [
                        {
                            "requirement_type": "anatomical location",
                            "expected_value": [
                                "urethra",
                                "ureters",
                                "upper tract",
                                "renal pelvis",
                                "bladder"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented FGF/FGFR alteration and have either 1a) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 1b) have not received chemotherapy due to poor ECOG status or 2) have insufficient renal function.",
            "criterions": [
                {
                    "exact_snippets": "Documented FGF/FGFR alteration",
                    "criterion": "FGF/FGFR alteration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy)",
                    "criterion": "previous treatment for metastatic or surgically unresectable urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "number of failed treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "chemotherapy",
                                "immunotherapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have not received chemotherapy due to poor ECOG status",
                    "criterion": "chemotherapy receipt",
                    "requirements": [
                        {
                            "requirement_type": "received chemotherapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "reason for not receiving chemotherapy",
                            "expected_value": "poor ECOG status"
                        }
                    ]
                },
                {
                    "exact_snippets": "have insufficient renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "sufficiency",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Inability or unwillingness to swallow pemigatinib or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib.",
            "criterions": [
                {
                    "exact_snippets": "Inability ... to swallow pemigatinib",
                    "criterion": "ability to swallow pemigatinib",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unwillingness to swallow pemigatinib",
                    "criterion": "willingness to swallow pemigatinib",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of pemigatinib",
                    "criterion": "gastrointestinal disorder(s) interfering with pemigatinib pharmacokinetics",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.",
                    "criterion": "use of potent CYP3A4 inhibitors or inducers",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior receipt of a selective FGFR inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior receipt of a selective FGFR inhibitor.",
                    "criterion": "selective FGFR inhibitor receipt",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}